-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Reata Pharmaceuticals (NASDAQ:RETA) Trading Up 4.6%
Reata Pharmaceuticals (NASDAQ:RETA) Trading Up 4.6%
Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) was up 4.6% during mid-day trading on Monday . The stock traded as high as $23.59 and last traded at $23.14. Approximately 14,495 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 674,305 shares. The stock had previously closed at $22.12.
Wall Street Analysts Forecast Growth
Separately, Robert W. Baird lowered their price objective on shares of Reata Pharmaceuticals from $37.00 to $27.00 and set a "neutral" rating on the stock in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Reata Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $57.57.
Get Reata Pharmaceuticals alerts:Reata Pharmaceuticals Price Performance
The stock's 50-day simple moving average is $26.54 and its two-hundred day simple moving average is $29.67. The firm has a market capitalization of $843.45 million, a P/E ratio of -2.72 and a beta of 1.16.
Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) last released its quarterly earnings data on Monday, August 8th. The company reported ($2.02) EPS for the quarter, missing the consensus estimate of ($1.90) by ($0.12). Reata Pharmaceuticals had a negative net margin of 3,045.98% and a negative return on equity of 190.87%. The business had revenue of $0.76 million for the quarter, compared to the consensus estimate of $1.46 million. During the same quarter last year, the business earned ($2.00) EPS. Reata Pharmaceuticals's revenue for the quarter was down 65.7% compared to the same quarter last year. On average, analysts forecast that Reata Pharmaceuticals, Inc. will post -8.37 earnings per share for the current fiscal year.Institutional Trading of Reata Pharmaceuticals
A number of institutional investors have recently modified their holdings of RETA. US Bancorp DE boosted its position in shares of Reata Pharmaceuticals by 930.5% during the 1st quarter. US Bancorp DE now owns 1,824 shares of the company's stock valued at $60,000 after acquiring an additional 1,647 shares during the last quarter. UBS Group AG boosted its holdings in Reata Pharmaceuticals by 42.2% in the second quarter. UBS Group AG now owns 2,558 shares of the company's stock valued at $78,000 after purchasing an additional 759 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in Reata Pharmaceuticals by 51.1% in the second quarter. Macquarie Group Ltd. now owns 2,768 shares of the company's stock valued at $84,000 after purchasing an additional 936 shares in the last quarter. Amalgamated Bank acquired a new stake in shares of Reata Pharmaceuticals in the first quarter valued at approximately $141,000. Finally, Virtus ETF Advisers LLC boosted its holdings in shares of Reata Pharmaceuticals by 282.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,684 shares of the company's stock valued at $150,000 after acquiring an additional 4,198 shares during the period. 76.00% of the stock is currently owned by institutional investors.
About Reata Pharmaceuticals
(Get Rating)
Reata Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.
See Also
- Get a free copy of the StockNews.com research report on Reata Pharmaceuticals (RETA)
- Three Consumer Stocks That Could Outperform In Q4
- Comcast is an Asset Bonanza Priced Cheap
- Will Synthetic Biology Firm Amyris Post Net Income In 2024?
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) was up 4.6% during mid-day trading on Monday . The stock traded as high as $23.59 and last traded at $23.14. Approximately 14,495 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 674,305 shares. The stock had previously closed at $22.12.
瑞塔製藥股份有限公司(納斯達克代碼:Reta-Get Rating)週一午盤上漲4.6%。該股最高交易價格為23.59美元,最後報23.14美元。午盤交易中,約有14,495股易手,較674,305股的日均成交量下降了98%。該股此前收盤價為22.12美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Separately, Robert W. Baird lowered their price objective on shares of Reata Pharmaceuticals from $37.00 to $27.00 and set a "neutral" rating on the stock in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Reata Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $57.57.
另外,羅伯特·W·貝爾德在8月9日星期二的一份研究報告中將Reata PharmPharmticals的股票目標價從37.00美元下調至27.00美元,並將該股的評級定為“中性”。一位股票研究分析師將該股的評級定為賣出,兩位分析師給出了持有評級,四位分析師給出了買入評級。根據MarketBeat的數據,Reata PharmPharmticals目前的共識評級為持有,平均目標價為57.57美元。
Reata Pharmaceuticals Price Performance
瑞塔醫藥價格表現
The stock's 50-day simple moving average is $26.54 and its two-hundred day simple moving average is $29.67. The firm has a market capitalization of $843.45 million, a P/E ratio of -2.72 and a beta of 1.16.
該股的50日簡單移動均線切入位為26.54美元,200日簡單移動均線切入位為29.67美元。該公司的市值為8.4345億美元,市盈率為-2.72,貝塔係數為1.16。
Institutional Trading of Reata Pharmaceuticals
瑞塔製藥的機構交易
A number of institutional investors have recently modified their holdings of RETA. US Bancorp DE boosted its position in shares of Reata Pharmaceuticals by 930.5% during the 1st quarter. US Bancorp DE now owns 1,824 shares of the company's stock valued at $60,000 after acquiring an additional 1,647 shares during the last quarter. UBS Group AG boosted its holdings in Reata Pharmaceuticals by 42.2% in the second quarter. UBS Group AG now owns 2,558 shares of the company's stock valued at $78,000 after purchasing an additional 759 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in Reata Pharmaceuticals by 51.1% in the second quarter. Macquarie Group Ltd. now owns 2,768 shares of the company's stock valued at $84,000 after purchasing an additional 936 shares in the last quarter. Amalgamated Bank acquired a new stake in shares of Reata Pharmaceuticals in the first quarter valued at approximately $141,000. Finally, Virtus ETF Advisers LLC boosted its holdings in shares of Reata Pharmaceuticals by 282.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,684 shares of the company's stock valued at $150,000 after acquiring an additional 4,198 shares during the period. 76.00% of the stock is currently owned by institutional investors.
一些機構投資者最近修改了對Reta的持股。US Bancorp DE在第一季度將其在Reata PharmPharmticals的股票頭寸增加了930.5%。US Bancorp DE現在擁有1,824股該公司股票,價值6萬美元,此前在上個季度又購買了1,647股。瑞銀集團在第二季度增持了Reata PharmPharmticals 42.2%的股份。瑞銀集團目前持有該公司2,558股股票,價值7.8萬美元,上一季度又購買了759股。麥格理集團有限公司在第二季度增持了51.1%的Reata PharmPharmticals股份。麥格理集團(Macquarie Group Ltd.)目前持有2,768股該公司股票,價值84,000美元,該公司在上個季度又購買了936股。合併銀行在第一季度收購了Reata製藥公司的新股份,價值約為141,000美元。最後,Virtus ETF Advisers LLC在第四季度增持了282.5%的Reata PharmPharmticals股票。Virtus ETF Advisers LLC現在擁有5684股該公司的股票,價值15萬美元,在此期間又購買了4198股。76.00%的股票目前由機構投資者持有。
About Reata Pharmaceuticals
關於瑞塔製藥公司
(Get Rating)
(獲取評級)
Reata Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.
瑞塔製藥公司是一家臨牀階段的生物製藥公司,為患有嚴重或危及生命的疾病的患者識別、開發和商業化新的療法。該公司正在開發第三階段臨牀試驗計劃,包括用於治療由Alport綜合徵引起的慢性腎臟疾病(CKD)以及與結締組織疾病相關的一種形式的肺動脈高壓的患者的甲基巴度索龍(Bardoxolone);治療Friedreich‘s共濟失調的第二階段臨牀試驗奧馬維酮;以及針對各種形式的CKD進行第二階段研究,如IgA腎病、1型和2型糖尿病CKD、高血壓CKD、局灶性節段性腎小球硬化等。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Reata Pharmaceuticals (RETA)
- Three Consumer Stocks That Could Outperform In Q4
- Comcast is an Asset Bonanza Priced Cheap
- Will Synthetic Biology Firm Amyris Post Net Income In 2024?
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
- 免費獲取StockNews.com關於Reata製藥的研究報告(RETA)
- 三隻可能在第四季度表現優異的消費類股
- 康卡斯特是廉價的資產財源
- 合成生物學公司Amyris將在2024年實現淨收益嗎?
- 卡特彼勒能否在下跌的市場中走得更高?
- Dave&Buster‘s能免受高通脹和低支出的影響嗎?
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《瑞塔醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Reata製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧